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Hypothesis: functional imaging (FI) using computer methods can be used to evaluate the 
additional benefits of extra fine particle formulations in long term steroid treatment of 
asthmatic patients. Due to the high sensitivity of the FI techniques, FI results could 
correlate better with clinical outcome compared to lung function tests (LFT). 
 
10 asthmatics (5M/<52y>) were treated with 2 inhalations BID of 
BECLO(100mug)/FORMO(6mug) Modulite®  for 6 months. Patients were either steroid 
naïve (n=2), partially (n=4) or completely (n=4) controlled under their current fine 
particle steroid treatment. LFT data and FI data were collected at baseline and after 6m of 
treatment. An asthma control score (ACS) was assessed to evaluate the clinical outcome. 
 
Results can be found in Table 1.  
 
This study showed that exhaled NO, airway resistance and FI are sensitive measures to 
detect changes in lung function after 6m of steroid treatment in extra fine particle 
formulation. In addition parameters such as NO and FI appear to correlate significantly 
with clinical outcome in contrast to the standard spirometry and bodyplethysmography 
values. In conclusion, FI proves to be a very sensitive technique to assess changes in lung 
function while also being a good marker for clinical outcome. 
 
Table 1 # 
 
baseline 6 months p R^2 p
FEV1 [%pred] 97.8 102.88 0.17 0.04 0.60
FEV1 [L] 2.988 3.179 0.17 0.06 0.49
FVC [L] 4.135 4.164 0.61 0.09 0.41
FEV1/FVC [%] 72.133719 75.414391 0.09 0.19 0.21
FRC [L] 3.387 3.246 0.59 0.05 0.52
TLC [L] 6.341 6.431 0.28 0.00 0.85
exNO [ppb] 51.16 15.86 0.05 * 0.44 0.04 *
sRaw [kPas] 1.5684 1.0898 0.01 * 0.11 0.36
iVaw [mm] 43955.963 48272.081 0.005 * 0.47 0.03 *
iRaw [kPas/L] 0.1037047 0.0389163 0.005 * 0.59 0.009 *
ACS 21 23.3 0.12
Changes in LF and FI parameters after 6m of steroid treatment and the correlation of observed 
changes in LF with clinical outcome (* for statistical significance)
correlation with ACSlung function change
 
 
